Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer Journal Article
| Authors: | Nordström, T.; Vickers, A.; Assel, M.; Lilja, H.; Grönberg, H.; Eklund, M. |
| Article Title: | Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer |
| Abstract: | Background: The four-kallikrein panel and the Prostate Health Index (PHI) have been shown to improve prediction of prostate cancer (PCa) compared with prostate-specific antigen (PSA). No comparison of the four-kallikrein panel and PHI has been presented. Objective: To compare the four-kallikrein panel and PHI for predicting PCa in an independent cohort. Design, setting, and participants: Participants were from a population-based cohort of PSA-tested men in Stockholm County. We included 531 men with PSA levels between 3 and 15 ng/ml undergoing first-time prostate biopsy during 2010-2012. Outcome measurements and statistical analysis: Models were fitted to case status. We computed calibration curves, the area under the receiver-operating characteristics curve (AUC), decision curves, and percentage of saved biopsies. Results and limitations: The four-kallikrein panel showed AUCs of 69.0 when predicting any-grade PCa and 71.8 when predicting high-grade cancer (Gleason score 7). Similar values were found for PHI: 70.4 and 71.1, respectively. Both models had higher AUCs than a base model with PSA value and age ( p < 0.0001 for both); differences between models were not significant. Sensitivity analyses including men with any PSA level or a previous biopsy did not materially affect our findings. Using 10% predicted risk of highgrade PCa by the four-kallikrein panel or PHI of 39 as cut-off for biopsy saved 29% of performed biopsies at a cost of delayed diagnosis for 10% of the men with high-grade cancers. Both models showed limited net benefit in decision analysis. The main study limitation was lack of digital rectal examination data and biopsy decision being based on PSA information. Conclusions: The four-kallikrein panel and PHI similarly improved discrimination when predicting PCa and high-grade PCa. Both are simple blood tests that can reduce the number of unnecessary biopsies compared with screening with total PSA, representing an important new option to reduce harm. Patient summary: Prostate-specific antigen screening is controversial due to limitations of the test. We found that two blood tests, the Prostate Health Index and the fourkallikrein panel, performed similarly and could both aid in decision making among Swedish men undergoing a prostate biopsy. © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| Keywords: | adult; controlled study; human tissue; aged; major clinical study; cancer risk; biomarkers; prostate specific antigen; calibration; prediction; prostate cancer; prostate-specific antigen; prostatic neoplasms; prostate biopsy; kallikrein; delayed diagnosis; observational study; receiver operating characteristic; digital rectal examination; diagnostic test accuracy study; kallikrein-related peptidases; human; male; priority journal; article; genital system disease assessment; four kallikrein panel; prostate health index |
| Journal Title: | European Urology |
| Volume: | 68 |
| Issue: | 1 |
| ISSN: | 0302-2838 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2015-07-01 |
| Start Page: | 139 |
| End Page: | 146 |
| Language: | English |
| DOI: | 10.1016/j.eururo.2014.08.010 |
| PROVIDER: | scopus |
| PMCID: | PMC4503229 |
| PUBMED: | 25151013 |
| DOI/URL: | |
| Notes: | Export Date: 2 November 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work